PD
VRTX icon

Point72 (DIFC)’s Vertex Pharmaceuticals VRTX Stock Holding History

Point72 (DIFC)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,624
Closed -$6.78M – 1933
2024
Q1 		$6.53M Buy
+15,624
New +$6.6M 0.21% 128

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Point72 (DIFC)'s VRTX Position: Q2 2024 in Review

Point72 (DIFC) sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 15,624 shares — an estimated $6.78M sold.

Point72 (DIFC) first reported a position in VRTX in Q1 2024 and held it in 1 quarter. The position peaked at $6.53M in Q1 2024. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Point72 (DIFC) reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Point72 (DIFC) sold 15,624 Vertex Pharmaceuticals shares in Q2 2024, an estimated $6.78M.
  • Point72 (DIFC) first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Point72 (DIFC)'s Vertex Pharmaceuticals position peaked at $6.53M in Q1 2024.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Point72 (DIFC)'s 13F filing for Q2 2024, filed 14 Aug 2024.